STING1 and neoplasm: Our study demonstrates that cGAS-STING pathway is frequently deficient in tumors, and its low expression is associated with poor immune infiltration, reduced immunotherapy responsiveness, and worse patient survival, highlighting its potential as a functional biomarker of tumor immunogenicity and a potential predictor of immunotherapy response.